<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; emerging</title>
	<atom:link href="http://www.tapanray.in/tag/emerging/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Create Novel Marketing Pathways As Covid Mutants Keep Emerging</title>
		<link>http://www.tapanray.in/create-novel-marketing-pathways-as-covid-mutants-keep-emerging/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=create-novel-marketing-pathways-as-covid-mutants-keep-emerging</link>
		<comments>http://www.tapanray.in/create-novel-marketing-pathways-as-covid-mutants-keep-emerging/#comments</comments>
		<pubDate>Mon, 10 Jan 2022 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[approvals]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[emergency]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[EUA]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[molnupiravir]]></category>
		<category><![CDATA[mutants]]></category>
		<category><![CDATA[novel]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[pathways]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[use]]></category>
		<category><![CDATA[vaccines]]></category>
		<category><![CDATA[variants]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10634</guid>
		<description><![CDATA[The World’s battle against wave after wave unsettling onslaught of Coronavirus on human lives and livelihood continues, since December 2019. The first wave was triggered by the novel Covid-19 from Wuhan in China, the second by its deadly – Delta variant, &#8230; <a href="http://www.tapanray.in/create-novel-marketing-pathways-as-covid-mutants-keep-emerging/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/create-novel-marketing-pathways-as-covid-mutants-keep-emerging/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Nutraceuticals: An Emerging Opportunity in The Gray Area Between Pharma And Nutrition</title>
		<link>http://www.tapanray.in/nutraceuticals-an-emerging-opportunity-in-the-gray-area-between-pharma-and-nutrition/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=nutraceuticals-an-emerging-opportunity-in-the-gray-area-between-pharma-and-nutrition</link>
		<comments>http://www.tapanray.in/nutraceuticals-an-emerging-opportunity-in-the-gray-area-between-pharma-and-nutrition/#comments</comments>
		<pubDate>Mon, 17 Nov 2014 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[A.T.Kearney]]></category>
		<category><![CDATA[area]]></category>
		<category><![CDATA[Ayush]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Coca]]></category>
		<category><![CDATA[Cola]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[dietary]]></category>
		<category><![CDATA[EBM]]></category>
		<category><![CDATA[EBN]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[evidence]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Frost&Sullivan]]></category>
		<category><![CDATA[FSSA]]></category>
		<category><![CDATA[FSSAI]]></category>
		<category><![CDATA[Gray]]></category>
		<category><![CDATA[Homeopathy]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Naturopathy]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Nutraceuticals]]></category>
		<category><![CDATA[nutrition]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Siddha]]></category>
		<category><![CDATA[supplement]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[Unani]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[Yoga]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6190</guid>
		<description><![CDATA[Close association between nutrition and health has assumed a historical relevance. Growing pieces of evidence, even today, suggests that nutritional intervention with natural substances could play an important role, especially in the preventive healthcare. The World Health Organization (WHO) too &#8230; <a href="http://www.tapanray.in/nutraceuticals-an-emerging-opportunity-in-the-gray-area-between-pharma-and-nutrition/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/nutraceuticals-an-emerging-opportunity-in-the-gray-area-between-pharma-and-nutrition/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Reaping rich harvest with less moaning and bagful of creative ideas from emerging Rural Markets of India</title>
		<link>http://www.tapanray.in/reaping-rich-harvest-with-less-moaning-and-bagful-of-creative-ideas-from-emerging-rural-markets-of-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=reaping-rich-harvest-with-less-moaning-and-bagful-of-creative-ideas-from-emerging-rural-markets-of-india</link>
		<comments>http://www.tapanray.in/reaping-rich-harvest-with-less-moaning-and-bagful-of-creative-ideas-from-emerging-rural-markets-of-india/#comments</comments>
		<pubDate>Mon, 07 May 2012 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[bagful]]></category>
		<category><![CDATA[BPL]]></category>
		<category><![CDATA[creative]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[From]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[harvest]]></category>
		<category><![CDATA[ideas]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[janaaushadhi]]></category>
		<category><![CDATA[less]]></category>
		<category><![CDATA[markets]]></category>
		<category><![CDATA[moaning]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reaping]]></category>
		<category><![CDATA[rich]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[urban]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=97</guid>
		<description><![CDATA[About 72 percent of the population and 135 million households of India live in the rural areas of the country. Many of them are poor. Definition of &#8216;Rural&#8217;: Agencies of the Government of India like, National Council of Applied Economic &#8230; <a href="http://www.tapanray.in/reaping-rich-harvest-with-less-moaning-and-bagful-of-creative-ideas-from-emerging-rural-markets-of-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/reaping-rich-harvest-with-less-moaning-and-bagful-of-creative-ideas-from-emerging-rural-markets-of-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India &#8211; Young Today, Old Tomorrow: Emerging Issues of Aging, Health and Socioeconomic Profile of the Country</title>
		<link>http://www.tapanray.in/india-young-today-old-tomorrow-emerging-issues-of-aging-health-and-socioeconomic-profile-of-the-country/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-young-today-old-tomorrow-emerging-issues-of-aging-health-and-socioeconomic-profile-of-the-country</link>
		<comments>http://www.tapanray.in/india-young-today-old-tomorrow-emerging-issues-of-aging-health-and-socioeconomic-profile-of-the-country/#comments</comments>
		<pubDate>Sun, 29 Apr 2012 01:30:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Aging]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Country]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Profile]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Socioeconomic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[Today]]></category>
		<category><![CDATA[Tomorrow]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[Young]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=100</guid>
		<description><![CDATA[‘World Health Day’ is celebrated every year on April 7, the day ‘World Health Organization (WHO)’ was founded in 1948. Each year, on this day, people from all walks of life across the globe are invited by WHO to focus &#8230; <a href="http://www.tapanray.in/india-young-today-old-tomorrow-emerging-issues-of-aging-health-and-socioeconomic-profile-of-the-country/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-young-today-old-tomorrow-emerging-issues-of-aging-health-and-socioeconomic-profile-of-the-country/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Explore the Emerging Markets with the &#8216;Wings of Courage&#8217;.</title>
		<link>http://www.tapanray.in/explore-the-emerging-markets-with-the-wings-of-courage/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=explore-the-emerging-markets-with-the-wings-of-courage</link>
		<comments>http://www.tapanray.in/explore-the-emerging-markets-with-the-wings-of-courage/#comments</comments>
		<pubDate>Mon, 07 Mar 2011 00:30:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[cliff]]></category>
		<category><![CDATA[containment]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Courage]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[Explore]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[markets]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[Wings]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=293</guid>
		<description><![CDATA[Overall growth rate of the global pharmaceutical industry is currently hovering around 5%. Similar situation has been prevailing since last several years. There is no indication of acceleration of growth rate from any of the top 3 regions of the &#8230; <a href="http://www.tapanray.in/explore-the-emerging-markets-with-the-wings-of-courage/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/explore-the-emerging-markets-with-the-wings-of-courage/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Quick implementation of the undiluted ‘Central Drug Authority (CDA)’ Bill is essential for emerging India</title>
		<link>http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india</link>
		<comments>http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india/#comments</comments>
		<pubDate>Mon, 21 Feb 2011 00:30:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Authority]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[CDA]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Central]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PSC]]></category>
		<category><![CDATA[Quick]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulations]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[undiluted]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=299</guid>
		<description><![CDATA[Many industry experts after having evaluated the provisions of the original draft proposal for forming a Central Drugs Authority (CDA) in the country, commended and supported this laudable initiative of the Government. This Bill also known as, “The Drugs &#38; &#8230; <a href="http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The traditional &#8216;Business Models&#8217; of R&amp;D focused Global Pharmaceutical majors are undergoing a metamorphosis</title>
		<link>http://www.tapanray.in/the-traditional-business-models-of-rd-focused-global-pharmaceutical-majors-are-undergoing-a-metamorphosis/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-traditional-business-models-of-rd-focused-global-pharmaceutical-majors-are-undergoing-a-metamorphosis</link>
		<comments>http://www.tapanray.in/the-traditional-business-models-of-rd-focused-global-pharmaceutical-majors-are-undergoing-a-metamorphosis/#comments</comments>
		<pubDate>Mon, 02 Aug 2010 00:30:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[are]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[BRIC]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[cliff]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[focused]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[majors]]></category>
		<category><![CDATA[markets]]></category>
		<category><![CDATA[Metamorphosis]]></category>
		<category><![CDATA[Models]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[undergoing]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=393</guid>
		<description><![CDATA[Mounting pressure on the P&#38;L account, as the products go off patent: Patented new products are the prime growth driver of the research based pharmaceutical companies of the world. Since last few years, because of various reasons, the number of &#8230; <a href="http://www.tapanray.in/the-traditional-business-models-of-rd-focused-global-pharmaceutical-majors-are-undergoing-a-metamorphosis/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-traditional-business-models-of-rd-focused-global-pharmaceutical-majors-are-undergoing-a-metamorphosis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Will Global Pharma Majors be successful in their foray into highly competitive generics pharma business offering no (patent) protection of any kind?</title>
		<link>http://www.tapanray.in/will-global-pharma-majors-be-successful-in-their-foray-into-highly-competitive-generics-pharma-business-offering-no-patent-protection-of-any-kind/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=will-global-pharma-majors-be-successful-in-their-foray-into-highly-competitive-generics-pharma-business-offering-no-patent-protection-of-any-kind</link>
		<comments>http://www.tapanray.in/will-global-pharma-majors-be-successful-in-their-foray-into-highly-competitive-generics-pharma-business-offering-no-patent-protection-of-any-kind/#comments</comments>
		<pubDate>Mon, 05 Jul 2010 01:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[any]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[cliff]]></category>
		<category><![CDATA[competitive]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[foray]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[highly]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[into]]></category>
		<category><![CDATA[kind]]></category>
		<category><![CDATA[majors]]></category>
		<category><![CDATA[markets]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[No]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[offering]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[successful]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[their]]></category>
		<category><![CDATA[Will]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=406</guid>
		<description><![CDATA[As reported by IMS Health, emerging markets will register a growth rate of 14% to 17% by 2014, when the developed markets will be growing by 3% to 6% during the same period. It is forecasted that the global pharmaceutical &#8230; <a href="http://www.tapanray.in/will-global-pharma-majors-be-successful-in-their-foray-into-highly-competitive-generics-pharma-business-offering-no-patent-protection-of-any-kind/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/will-global-pharma-majors-be-successful-in-their-foray-into-highly-competitive-generics-pharma-business-offering-no-patent-protection-of-any-kind/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Quick implementation of the UNDILUTED ‘Central Drug Authority (CDA)’ Bill is essential for emerging India</title>
		<link>http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india-2/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india-2</link>
		<comments>http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india-2/#comments</comments>
		<pubDate>Sun, 31 Jan 2010 01:30:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Authority]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[CDA]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Central]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[MoH]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Quick]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[undiluted]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=476</guid>
		<description><![CDATA[Many industry experts after having carefully evaluated the provisions of the original draft of the proposal of forming a CDA in the country commended and supported this praiseworthy initiative of the Government. This Bill also known as, “The Drugs &#38; &#8230; <a href="http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india-2/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/quick-implementation-of-the-undiluted-central-drug-authority-cda-bill-is-essential-for-emerging-india-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Emerging markets and a robust oncology portfolio expected to be the future growth engine of the global pharmaceutical industry&#8230; but not without associated pricing pressures.</title>
		<link>http://www.tapanray.in/emerging-markets-and-a-robust-oncology-portfolio-expected-to-be-the-future-growth-engine-of-the-global-pharmaceutical-industry-but-not-without-associated-pricing-pressures/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=emerging-markets-and-a-robust-oncology-portfolio-expected-to-be-the-future-growth-engine-of-the-global-pharmaceutical-industry-but-not-without-associated-pricing-pressures</link>
		<comments>http://www.tapanray.in/emerging-markets-and-a-robust-oncology-portfolio-expected-to-be-the-future-growth-engine-of-the-global-pharmaceutical-industry-but-not-without-associated-pricing-pressures/#comments</comments>
		<pubDate>Thu, 08 Oct 2009 01:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[associated]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[But]]></category>
		<category><![CDATA[cliff]]></category>
		<category><![CDATA[containment]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[engine]]></category>
		<category><![CDATA[expected]]></category>
		<category><![CDATA[future]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[markets]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[portfolio]]></category>
		<category><![CDATA[pressures]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Robust]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[without]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=760</guid>
		<description><![CDATA[When the growth rate of the developed markets of the global pharmaceutical industry started slowing down along with the declining R&#38;D productivity, the emerging markets were identified as the new ‘El-Dorado’ by the global players. At the same time, new &#8230; <a href="http://www.tapanray.in/emerging-markets-and-a-robust-oncology-portfolio-expected-to-be-the-future-growth-engine-of-the-global-pharmaceutical-industry-but-not-without-associated-pricing-pressures/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/emerging-markets-and-a-robust-oncology-portfolio-expected-to-be-the-future-growth-engine-of-the-global-pharmaceutical-industry-but-not-without-associated-pricing-pressures/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
